Antibiotics Active Pharmaceutical Ingredient (API) Market Research Conclusions|Business Plans|Strategies with Forecast 2020 – 2030

The demand for antibiotics API will continue rising at a steady pace between 2021 and 2031. It is often the first choice to treat infections. According to a new study by Future Market Insights (FMI), the antibiotics API market is likely to surpass US$ 8.1 Bn in 2021. Antibiotics are intended to make medical procedures much safer.

Any surgery or chronic diseases is susceptible to the bacterial infection, putting the patient at the greater risk. The increasing incidence of infections such as tuberculosis, pneumonia, blood poisoning, gonorrhea, and foodborne diseases would cause surge demand for antibiotics that expects to drive the antibiotics API market.

As per the World Health Organization (WHO), pneumonia caused by bacteria can be treated with antibiotics. Around 15% of the children deaths was accounted due to pneumonia in 2017. According to UNICEF data 2018, worldwide, there are around 1,400 cases of pneumonia per 100,000 children, with the greatest incidence occurring in South Asia (2,500 cases per 100,000 children) and West and Central Africa (1,620 cases per 100,000 children)

To Get Sample Copy of Report visit @ https://www.futuremarketinsights.com/reports/sample/rep-gb-13025

Pandemic COVID-19 is believed to have a negative impact on the antibiotics API market. Some of the leading biotech companies, research institutes, and pharmaceutical companies are appointed in collaboration work to deal with the situation. This has shifted their focus and resources from making other drugs to coronavirus vaccines. The shortage of various API’s, and restricted hospital visits due to the increasing pool of COVID-19 patients have jolted the global antibiotics API market. 

In terms of API, penicillin antibiotics segment dominated the antibiotics API market with a market share of 51.1% in 2021 owing to the increasing demand and adoption of penicillin as a first-line antibiotic therapy to treat several bacterial infections. Pharmaceutical companies are expected to rule the end user segment. They are expected to hold over 77% of the market and remain dominant through the forecast period.

Key Takeaways from Antibiotics API Market Study

  • The global antibiotics API market is estimated to be US$ 8.01 Bn in 2020, with the market expected to exhibit a CAGR of 3.1% during the forecast period (2020-2030) 
  • The U.S. holds over 92.1% share of the North America market, but Canada is projected to expand faster CAGR
  • The U.K. market will showcase steady y-o-y growth at 2.1% in 2021
  • The demand from Germany and France will rise at a positive rate through the forecast period
  • Within East Asia China will emerge as a key market, while Japan and South Korea will continue exhibiting steady demand

“Increasing prevalence of bacterial diseases, extreme use of antibiotics and rising investment in R&D are expected to boost the growth of the antibiotics API market.” says the FMI Analyst

Rising investment in R&D sector in order to develop advanced molecules is the major factor expected to boost the antibiotic API market growth.

For instance, Sandoz, the Novartis biosimilars and generics division, undergoes a joint investment, with the Austrian federal government, to enhance the long-term future of integrated antibiotics manufacturing in Europe.

Key players in the Antibiotics API are Entering into Strategic Alliance

 The top players are focusing on increasing acquisitions at regional levels. Acquisitions empower the company with products and increase the company’s portfolio. The company acquires to possess well-established products and solutions that expects to account good revenue source for the acquirer. This also enables the company to enter new emerging markets as well as enhance the existing markets.

For instance, in August 2019, Nanjing Dorra Pharmaceutical Technology collaborated with Meitheal Pharmaceuticals, the fully integrated generic injectables company, for elevating the manufacturing capacity of the active pharmaceutical ingredients in the region of U.S. The collaboration enabled Meitheal Pharmaceuticals to invest into the Nanjing Dorra Pharmaceutical Technology.

Who is Winning?

The global antibiotics API market is set to expand its scope in the forecast period, as a result of rising prevalence of various bacterial diseases, and growing investment in R&D. The antibiotics market is highly competitive and consists of several major players. Pharmaceutical companies are more focused towards outsourcing of antibiotics API manufacturing due to the involvement of high capital investment in the establishment of Antibiotics API manufacturing units.

The key market players covered by FMI include Sandoz International GmbH, Centrient Pharmaceuticals, CordenPharma International, ACS DOBFAR SPA, Nanjing Dorra Pharmaceutical Technology Co. Ltd., DAEWOONG PHARMACEUTICAL CO. LTD., Parabolic Drugs Ltd., Penam Laboratories Ltd., ASIATIC DRUGS & PHARMACEUTICALS PVT. LTD., Fresenius Kabi, The United Laboratories International Holdings Limited, Aurobindo Pharma Limited, Unimark Remedies Ltd., Savior Lifetec, Shenzhen Haibin Pharmaceutical Co., Ltd., Sterile India Pvt. Ltd., Zhejiang Jiuzhou Pharmaceutical Co. Ltd., and Kyongbo Pharm, consolidating their positions through mergers, acquisitions and new product launches.

Antibiotics API Market by API Type

API Type

  • Penicillin Antibiotics
    • Ampicillin
    • Amoxicillin
    • Dicloxacillin
    • Penicillin G Sodium
    • Benzathine
    • Procaine
  • Cephalosporins
    • Cefotaxime
    • Ceftriaxone
    • Cefuroxime
    • Cefalotin
  • Carbapenem Antibiotics
    • Meropenem
    • Imipenem
    • Ertapenem 

End User

  • Pharmaceutical Companies
  • Contract Manufacturing Organizations (CMOs)
  • Contract Development & Manufacturing Organizations (CDMOs)

Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Middle East and Africa (MEA)
  • Oceania

Leave a comment

Your email address will not be published. Required fields are marked *